Investor Presentaiton

12 Commercial execution and innovation Diabetes care Novo NordiskⓇ RybelsusⓇ has only just started to be commercially available in IO with Japan being the biggest opportunity RybelsusⓇ is Novo Nordisk's entry into 55% of the diabetes market IO diabetes market is DKK ~200 billion Strong start for RybelsusⓇ in Japan's DKK 20 billion MOAD market after 14-day prescription restriction was lifted TRX ('000) 45% injectable 55% oral 100 80 60 60 60 25% 24% 40 40 46% 20 75% 20 OAD Traditional OAD MOAD 30% 0 1 5 9 Restriction lifted¹ 17 MOAD Months after launch Japan Next 12 countries -RybelsusⓇ All other countries canagliflozin -ipragliflozin -empagliflozin ―dapagliflozin ¹Time for the 14-day prescription restriction lifted for the respective products OAD: Oral anti-diabetes; MOAD: modern oral anti-diabetes market; IO: International Operations Source: IQVIA value spot rate December 2021, IQVIA LRX December 2021 CMD22 CAPITAL MARKETS DAY

View entire presentation